1. Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis 
Bruce C. Trapnell, Steven D. Strausbaugh, Marlyn S. Woo, Shin-Yir Tong, Steven A. Silber, Andrew E. Mulberg, Gerhard Leitz 
Journal of Cystic Fibrosis 
Volume 10, Issue 5, Pages (September 2011)
DOI: /j.jcf
Copyright © Terms and Conditions

2. Fig. 1
Disposition of the study participants. PERT, pancreatic enzyme replacement therapy; CFA, coefficient of fat absorption.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © Terms and Conditions

3. Fig. 2
Individual participant data for (A) change in coefficient of fat absorption (CFA) and (B) change in coefficient of nitrogen absorption (CNA) between the open-label phase and double-blind phase for placebo (n=20) or PANCREAZE® (n=20).
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © Terms and Conditions